MedPath

Clinical and Laboratory Study of Lysozyme Deposition on Daily Disposable Contact Lenses

Not Applicable
Completed
Conditions
Visual Acuity
Interventions
Device: etafilcon A
Device: nelfilcon A
Registration Number
NCT02365298
Lead Sponsor
Johnson & Johnson Vision Care, Inc.
Brief Summary

In vitro studies show that some hydrogel materials uptake more lysozyme than other hydrogel materials and that this protein remains largely active and promotes reduced cytokine response in an in vitro culture of human corneal epithelial cells. This study investigates whether these data transfer to the in vivo situation.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
28
Inclusion Criteria
  1. The subject must read, understand, and sign the Statement of Informed Consent and receive a fully executed copy of the form.
  2. The subject must appear able and willing to adhere to the instructions set forth in the clinical protocol.
  3. The subject must be willing to follow instructions and maintain the appointment schedule.
  4. The subject must be between 18 and 40 years of age (inclusive).
  5. The subject's vertex corrected spherical equivalent distance refraction must be in the range of -0.50D to -6.00D in each eye (inclusive).
  6. The subject's refractive cylinder must not exceed -1.25DC in each eye after vertexing to the corneal plane.
  7. The subject must be a current wearer of spherical, soft contact lenses (no toric, bifocal or multifocal contact lenses, no extended wear or monovision) for at least 5 days/week and at least 8 hours/day during to month prior to enrollment.
  8. The subject must own a wearable pair of spectacles and wear them the day of the initial visit.
  9. The subject must be an existing wearer of spherical soft contact lenses in both eyes.
  10. The subject must have normal eye (i.e., no ocular medications or infections of any type).
  11. The subject must be able to wear the study lenses for a minimum seven hours per day.
Exclusion Criteria
  1. Any ocular or systemic allergies or diseases that may interfere with contact lens wear (at the investigator's discretion).
  2. Any systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear (at the investigator's discretion).
  3. Currently pregnant or lactating (subjects who become pregnant during the study will be discontinued).
  4. Any infectious disease (e.g., hepatitis, tuberculosis) or a contagious immunosuppressive disease.
  5. Any active ocular infection.
  6. Is using any topical medication including artificial tears (ATS) up to two weeks prior to the screening visit.
  7. Any participants whose habitual contact lenses are used as an extended wear regimen.
  8. Entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, or moderate or above corneal distortion by keratometry.
  9. Clinically significant (grade 3 or 4) corneal edema, corneal vascularization, corneal staining, or any other abnormalities of the cornea which would contraindicate contact lens wear; clinically significant (grade 3 or 4) tarsal abnormalities or bulbar injection which might interfere with contact lens wear.
  10. Any know hypersensitivity or allergic reaction to study products.
  11. Participation in any contact lens or lens care product clinical trial within seven days prior to study enrollment.
  12. Employee or family member of the Center for Contact Lens Research (e.g., Investigator, Coordinator, Technician).

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
nelfilcon Anelfilcon AWorn in a daily disposable modality
etafilcon Aetafilcon AWorn in a daily disposable modality
etafilcon Anelfilcon AWorn in a daily disposable modality
nelfilcon Aetafilcon AWorn in a daily disposable modality
Primary Outcome Measures
NameTimeMethod
Quantity of Cytokines and Albumin in Tear Fluid12 wks after baseline

Measured cytokines: IL-1β, IL-2, IL-6, IL-8, IL-10, IL-12, IL-13, and TNF-alpha. Measurement will be taken after the subject has worn the lenses for a full seven hours. During the 2nd period subjects continued wearing the current lens that they were randomized to for an additional 6 weeks of wear.

Total Protein and Total Lysosome Deposits6 wks after baseline

Measurement will be taken after the subject has worn the lenses for a full seven hours

Total Protein and Lysosome Deposits12 wks after baseline

Measurement will be taken after the subject has worn the lenses for a full seven hours

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

University of Waterloo

🇨🇦

Waterloo, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath